Alzheimer's & dementia : the journal of the Alzheimer's Association
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Visual read of [F-18]florquinitau PET that includes and extends beyond the mesial temporal lobe is associated with increased plasma pTau217 and cognitive decline in a cohort that is enriched with risk for Alzheimer's disease.
2024
-
An international core outcome set for primary progressive aphasia (COS-PPA): Consensus-based recommendations for communication interventions across research and clinical settings.
2024
-
Dementia risk scores, apolipoprotein E, and risk of Alzheimer's disease: One size does not fit all.
2024
-
Better cardiovascular health is associated with slowed clinical progression in autosomal dominant frontotemporal lobar degeneration variant carriers..
20:6820-6833.
2024
-
Pathways to personalized medicine-Embracing heterogeneity for progress in clinical therapeutics research in Alzheimer's disease..
20:7384-7394.
2024
-
Bridging the gap: Multi-omics profiling of brain tissue in Alzheimer's disease and older controls in multi-ethnic populations..
20:7174-7192.
2024
-
Alzheimer's disease CSF biomarkers correlate with early pathology and alterations in neuronal and glial gene expression..
20:7090-7103.
2024
-
Psychosocial implications of learning amyloid PET results in an observational cohort..
20:6579-6589.
2024
-
Clonal hematopoiesis of indeterminate potential is associated with reduced risk of cognitive impairment in patients with chronic kidney disease..
20:6960-6971.
2024
-
A genetic and proteomic comparison of key AD biomarkers across tissues.
2024
-
A genome-wide association meta-analysis of all-cause and vascular dementia..
20:5973-5995.
2024
-
Predicting continuous amyloid PET values with CSF tau phosphorylation occupancies.
2024
-
Spatial extent as a sensitive amyloid-PET metric in preclinical Alzheimer's disease..
20:5434-5449.
2024
-
Novel measures of cognition and function for the AD spectrum in the Novel Measures for Alzheimer's Disease Prevention Trials (NoMAD) project: Psychometric properties, convergent validation, and contrasts with established measures..
20:5089-5101.
2024
-
Extended genome-wide association study employing the African genome resources panel identifies novel susceptibility loci for Alzheimer's disease in individuals of African ancestry..
20:5247-5261.
2024
-
Neuropsychiatric symptom burden in early-onset and late-onset Alzheimer's disease as a function of age..
20:5481-5491.
2024
-
The role of the Alzheimer's Disease Neuroimaging Initiative in establishing the Dominantly Inherited Alzheimer Network.
2024
-
Assessing amyloid PET positivity and cognitive function in Down syndrome to guide clinical trials targeting amyloid..
20:5570-5577.
2024
-
Correlates of missed or late versus timely diagnosis of dementia in healthcare settings.
2024
-
Pharmacoepidemiology evaluation of bumetanide as a potential candidate for drug repurposing for Alzheimer's disease..
20:5236-5246.
2024
-
Relationships between PET and blood plasma biomarkers in corticobasal syndrome..
20:4765-4774.
2024
-
Unraveling the multiple chronic conditions patterns among people with Alzheimer's disease and related dementia: A machine learning approach to incorporate synergistic interactions..
20:4818-4827.
2024
-
Decentralized clinical trials for medications to reduce the risk of dementia: Consensus report and guidance..
20:4625-4634.
2024
-
Post-GWAS multiomic functional investigation of the TNIP1 locus in Alzheimer's disease highlights a potential role for GPX3..
20:5044-5053.
2024
-
Characterizing molecular and synaptic signatures in mouse models of late-onset Alzheimer's disease independent of amyloid and tau pathology..
20:4126-4146.
2024
-
Sleep-wake behavior, perceived fatigability, and cognitive reserve in older adults..
20:4020-4031.
2024
-
Data-driven decomposition and staging of flortaucipir uptake in Alzheimer's disease..
20:4002-4019.
2024
-
Atrophy links lower novelty-related locus coeruleus connectivity to cognitive decline in preclinical AD..
20:3958-3971.
2024
-
α-Synuclein seed amplification assay detects Lewy body co-pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden..
20:4351-4365.
2024
-
Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trial..
20:3827-3838.
2024
-
White matter hyperintensities and the surrounding normal appearing white matter are associated with water channel disruption in the oldest old..
20:3839-3851.
2024
-
Data-driven classification of cognitively normal and mild cognitive impairment subtypes predicts progression in the NACC dataset..
20:3442-3454.
2024
-
Longitudinal normative standards for cognitive tests and composites using harmonized data from two Wisconsin AD-risk-enriched cohorts..
20:3305-3321.
2024
-
Delineating cognitive resilience using fractal regulation: Cross-sectional and longitudinal evidence from the Rush Memory and Aging Project..
20:3203-3210.
2024
-
Genetic associations with dementia-related proteinopathy: Application of item response theory..
20:2906-2921.
2024
-
Investigating the impact of hypertension with and without diabetes on Alzheimer's disease risk: A clinico-pathological study..
20:2766-2778.
2024
-
Whole genome-wide sequence analysis of long-lived families (Long-Life Family Study) identifies MTUS2 gene associated with late-onset Alzheimer's disease..
20:2670-2679.
2024
-
The dementia care study (D-CARE): Recruitment strategies and demographic characteristics of participants in a pragmatic randomized trial of dementia care..
20:2575-2588.
2024
-
Lewy body pathology modifies risk factors for cerebral amyloid angiopathy when comorbid with Alzheimer's disease pathology..
20:2564-2574.
2024
-
INviting Veterans InTo Enrollment in Alzheimer's Disease Research Centers (INVITE-ADRC): An NIA and VA-sponsored initiative to increase veteran participation in aging and dementia research..
20:3088-3098.
2024
-
Artificial Intelligence and Technology Collaboratories: Innovating aging research and Alzheimer's care..
20:3074-3079.
2024
-
Developing and describing a typology of lucid episodes among people with Alzheimer's disease and related dementias..
20:2434-2443.
2024
-
COVID-19 pandemic's relationship with enrollment at US Alzheimer's Disease Research Centers..
20:2408-2419.
2024
-
Microglia measured by TSPO PET are associated with Alzheimer's disease pathology and mediate key steps in a disease progression model..
20:2397-2407.
2024
-
Cross-national comparisons of later-life cognitive function using data from the Harmonized Cognitive Assessment Protocol (HCAP): Considerations and recommended best practices..
20:2273-2281.
2024
-
Lewy body dementia: Overcoming barriers and identifying solutions..
20:2298-2308.
2024
-
Predictors and outcomes of fluctuations in the clinical dementia rating scale..
20:2080-2088.
2024
-
Scalable plasma and digital cognitive markers for diagnosis and prognosis of Alzheimer's disease and related dementias..
20:2089-2101.
2024
-
Genetic risk score for Alzheimer's disease predicts brain volume differences in mid and late life in UK biobank participants..
20:1978-1987.
2024
-
Lifetime occupational skill and later-life cognitive function among older adults in the United States, Mexico, India, and South Africa..
20:1933-1943.
2023
-
Significance of a positive tau PET scan with a negative amyloid PET scan..
20:1923-1932.
2023
-
Blood-based biomarkers for Alzheimer's disease and cognitive function from mid- to late life..
20:1807-1814.
2023
-
Impact of the iWHELD digital person-centered care program on quality of life, agitation and psychotropic medications in people with dementia living in nursing homes during the COVID-19 pandemic: A randomized controlled trial..
20:1797-1806.
2023
-
Cerebrovascular reactivity in Alzheimer's disease signature regions is associated with mild cognitive impairment in adults with hypertension..
20:1784-1796.
2023
-
Pathology-specific patterns of cerebellar atrophy in neurodegenerative disorders..
20:1771-1783.
2023
-
Associations Between Social Network Characteristics and Brain Structure Among Older Adults..
20:1406-1420.
2023
-
Longitudinal change in memory performance as a strong endophenotype for Alzheimer's disease..
20:1268-1283.
2023
-
Microglial immunometabolism endophenotypes contribute to sex difference in Alzheimer's disease..
20:1334-1349.
2023
-
Sex-specific genetic architecture of late-life memory performance..
20:1250-1267.
2023
-
Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease..
20:1214-1224.
2023
-
Psychosocial factors associated with 7-year change in cognition among middle-aged and older Hispanics/Latinos: The Hispanic Community Health Study/Study of Latinos-Investigation of Neurocognitive Aging (SOL-INCA) and Sociocultural ancillary studies..
20:1137-1148.
2023
-
Alzheimer's polygenic risk scores are associated with cognitive phenotypes in Down syndrome..
20:1038-1049.
2023
-
Whole genome methylation sequencing in blood identifies extensive differential DNA methylation in late-onset dementia due to Alzheimer's disease..
20:1050-1062.
2023
-
The Sporadic Early-onset Alzheimer's Disease Signature Of Atrophy: Preliminary Findings From The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) Cohort..
19 Suppl 9:S74-S88.
2023
-
Heterogeneous treatment effects of metformin on risk of dementia in patients with type 2 diabetes: A longitudinal observational study..
20:975-985.
2023
-
Pathogenic variants in the Longitudinal Early-onset Alzheimer's Disease Study cohort..
19 Suppl 9:S64-S73.
2023
-
Spatial proteomics of hippocampal subfield-specific pathology in Alzheimer's disease and primary age-related tauopathy..
20:783-797.
2023
-
Health care utilization and costs in the years preceding dementia identification..
19:5852-5859.
2023
-
Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer's Disease Study (LEADS)..
19 Suppl 9:S98-S114.
2023
-
Identifying individuals with non-Alzheimer's disease co-pathologies: A precision medicine approach to clinical trials in sporadic Alzheimer's disease..
20:421-436.
2023
-
Influence of amyloid and diagnostic syndrome on non-traditional memory scores in early-onset Alzheimer's disease..
19 Suppl 9:S29-S41.
2023
-
Plasma phosphorylated tau-217 exhibits sex-specific prognostication of cognitive decline and brain atrophy in cognitively unimpaired adults..
20:376-387.
2023
-
Mapping sleep's oscillatory events as a biomarker of Alzheimer's disease..
20:301-315.
2023
-
Different cohort, disparate results: Selection bias is a key factor in autopsy cohorts..
20:266-277.
2023
-
Risk factors for dementia in older intensive care unit (ICU) survivors..
20:278-287.
2023
-
DNA from multiple viral species is associated with Alzheimer's disease risk..
20:253-265.
2023
-
White matter hyperintensity longitudinal morphometric analysis in association with Alzheimer disease..
19:4488-4497.
2023
-
Effect of exercise engagement and cardiovascular risk on neuronal injury..
19:4454-4462.
2023
-
Advancing specificity in delirium: The delirium subtyping initiative..
20:183-194.
2023
-
Novel methodology for detection and prediction of mild cognitive impairment using resting-state EEG..
20:145-158.
2023
-
Sex and APOE ε4 carrier effects on atrophy, amyloid PET, and tau PET burden in early-onset Alzheimer's disease..
19 Suppl 9:S49-S63.
2023
-
Cerebrospinal fluid biomarkers in the Longitudinal Early-onset Alzheimer's Disease Study..
19 Suppl 9:S115-S125.
2023
-
White matter hyperintensities are higher among early-onset Alzheimer's disease participants than their cognitively normal and early-onset nonAD peers: Longitudinal Early-onset Alzheimer's Disease Study (LEADS)..
19 Suppl 9:S89-S97.
2023
-
Biomarker disclosure protocols in prodromal Alzheimer's disease clinical trials..
19:4270-4275.
2023
-
A simulative deep learning model of SNP interactions on chromosome 19 for predicting Alzheimer's disease risk and rates of disease progression..
19:5690-5699.
2023
-
Developments in understanding early onset Alzheimer's disease..
19 Suppl 9:S126-S131.
2023
-
Demographically-adjusted normative data among Latinos for the version 3 of the Alzheimer's Disease Centers' Neuropsychological Test Battery in the Uniform Data Set..
19:4174-4186.
2023
-
Is the association between cognitive disease progression and atrial fibrillation modified by sex?.
19:4163-4173.
2023
-
Predicting amyloid-beta pathology in the general population..
19:5506-5517.
2023
-
Baseline neuropsychiatric symptoms and psychotropic medication use midway through data collection of the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort..
19 Suppl 9:S42-S48.
2023
-
Gaps in clinical research in frontotemporal dementia: A call for diversity and disparities-focused research..
19:5817-5836.
2023
-
Novel loci for Alzheimer's disease identified by a genome-wide association study in Ashkenazi Jews..
19:5550-5562.
2023
-
Profiling baseline performance on the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort near the midpoint of data collection..
19 Suppl 9:S8-S18.
2023
-
Learning slopes in early-onset Alzheimer's disease..
19 Suppl 9:S19-S28.
2023
-
Global rural health disparities in Alzheimer's disease and related dementias: State of the science..
19:4204-4225.
2023
-
Subjective cognitive decline across ethnoracial groups in the A4 study..
19:4084-4093.
2023
-
Large-scale proteome and metabolome analysis of CSF implicates altered glucose and carbon metabolism and succinylcarnitine in Alzheimer's disease..
19:5447-5470.
2023
-
Preserved autophagy in cognitively intact non-demented individuals with Alzheimer's neuropathology..
19:5355-5370.
2023
-
Validation of newly derived polygenic risk scores for dementia in a prospective study of older individuals..
19:5333-5342.
2023
-
Sex-specific declines in cholinergic-targeting tRNA fragments in the nucleus accumbens in Alzheimer's disease..
19:5159-5172.
2023
-
The epidemiology of mild cognitive impairment, Alzheimer's disease and related dementia in U.S. veterans..
19:3977-3984.
2023
-
Research diagnostic criteria for mild cognitive impairment with Lewy bodies: A systematic review and meta-analysis..
19:3186-3202.
2023
-
The structural and social determinants of Alzheimer's disease related dementias..
19:3171-3185.
2023
-
Social enrichment on the job: Complex work with people improves episodic memory, promotes brain reserve, and reduces the risk of dementia..
19:2655-2665.
2023
-
Sex differences in associations between APOE ε2 and longitudinal cognitive decline..
19:4651-4661.
2023
-
Genetic associations with age at dementia onset in the PSEN1 E280A Colombian kindred..
19:3835-3847.
2023
-
Racial and ethnic differences in neuropsychiatric symptoms and progression to incident cognitive impairment among community-dwelling participants..
19:3635-3643.
2023
-
Sex-specific effects of SNAP-25 genotype on verbal memory and Alzheimer's disease biomarkers in clinically normal older adults..
19:3448-3457.
2023
-
Preclinical and translational models for delirium: Recommendations for future research from the NIDUS delirium network..
19:2150-2174.
2023
-
Outcome measures for Alzheimer's disease: A global inter-societal Delphi consensus..
19:2707-2729.
2023
-
APOE ε4 is associated with earlier symptom onset in LOAD but later symptom onset in EOAD..
19:2212-2217.
2023
-
Acute sleep loss decreases CSF-to-blood clearance of Alzheimer's disease biomarkers..
19:3055-3064.
2023
-
Catalyzing dementia care through the learning health system and consumer health information technology..
19:2197-2207.
2023
-
Initial non-amnestic symptoms relate to faster rate of functional and cognitive decline compared to amnestic symptoms in neuropathologically confirmed dementias..
19:2956-2965.
2023
-
Predictors of falls in older adults with and without dementia..
19:2888-2897.
2023
-
Plasma p-tau217 predicts in vivo brain pathology and cognition in autosomal dominant Alzheimer's disease..
19:2585-2594.
2022
-
AD and non-AD mediators of the pathway between the APOE genotype and cognition..
19:2508-2519.
2022
-
Cognition, function, and prevalent dementia in centenarians and near-centenarians: An individual participant data (IPD) meta-analysis of 18 studies..
19:2265-2275.
2022
-
APOE ε4 carrier status and sex differentiate rates of cognitive decline in early- and late-onset Alzheimer's disease..
19:1983-1993.
2022
-
Baseline characterization of the ARMADA (Assessing Reliable Measurement in Alzheimer's Disease) study cohorts..
19:1974-1982.
2022
-
Pulse pressure trajectories predict brain microstructure in community-dwelling older adults: Associations with executive function and modification by APOE..
19:1963-1973.
2022
-
Improving generalizability and study design of Alzheimer's disease cohort studies in the United States by including under-represented populations..
19:1549-1557.
2022
-
Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays..
19:1913-1924.
2022
-
Leukocyte surface biomarkers implicate deficits of innate immunity in sporadic Alzheimer's disease..
19:2084-2094.
2022
-
Population-based discovery and Mendelian randomization analysis identify telmisartan as a candidate medicine for Alzheimer's disease in African Americans..
19:1876-1887.
2022
-
Metabolomic and lipidomic signatures in autosomal dominant and late-onset Alzheimer's disease brains..
19:1785-1799.
2022
-
A flexible modeling approach for biomarker-based computation of absolute risk of Alzheimer's disease dementia..
19:1452-1465.
2022
-
Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease..
19:708-720.
2022
-
To donate, or not to donate, that is the question: Latino insights into brain donation..
19:1274-1280.
2022
-
Biomarkers of Alzheimer syndrome and related dementias: A&D author's guide..
18:1595-1601.
2022
-
White matter hyperintensities in former American football players..
19:1260-1273.
2022
-
The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease..
19:1227-1233.
2022
-
Alzheimer's disease medication use and adherence patterns by race and ethnicity..
19:1184-1193.
2022
-
Using Alzheimer's disease blood tests to accelerate clinical trial enrollment..
19:1175-1183.
2022
-
Phosphorylated tau sites that are elevated in Alzheimer's disease fluid biomarkers are visualized in early neurofibrillary tangle maturity levels in the post mortem brain..
19:1029-1040.
2022
-
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease..
18:2669-2686.
2022
-
Elevated blood pressure is associated with advanced brain aging in mid-life: A 30-year follow-up of The CARDIA Study..
19:924-932.
2022
-
Toward harmonization of strategies for investigating lucidity in AD/ADRD: A preliminary research framework..
19:343-352.
2022
-
APOE ε4 influences medial temporal atrophy and tau deposition in atypical Alzheimer's disease..
19:784-796.
2022
-
Pattern and implications of neurological examination findings in autosomal dominant Alzheimer disease..
19:632-645.
2022
-
Biomarker clustering in autosomal dominant Alzheimer's disease..
19:274-284.
2022
-
Daytime napping and Alzheimer's dementia: A potential bidirectional relationship..
19:158-168.
2022
-
Waning locus coeruleus integrity precedes cortical tau accrual in preclinical autosomal dominant Alzheimer's disease..
19:169-180.
2022
-
"Exceptions that prove the rule"-Why have clinical trials failed to show efficacy of risk factor interventions suggested by observational studies of the dementia-Alzheimer's disease syndrome?.
18:389-392.
2022
-
Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing..
18:1969-1979.
2022
-
Racial differences in longitudinal Alzheimer's disease biomarkers among cognitively normal adults..
18:2570-2581.
2022
-
Screening and enrollment of underrepresented ethnocultural and educational populations in the Alzheimer's Disease Neuroimaging Initiative (ADNI)..
18:2603-2613.
2022
-
The complex relationship between depression and progression to incident cognitive impairment across race and ethnicity..
18:2593-2602.
2022
-
Addressing the disparities in dementia risk, early detection and care in Latino populations: Highlights from the second Latinos & Alzheimer's Symposium..
18:1677-1686.
2022
-
Alzheimer's disease research progress in the Mediterranean region: The Alzheimer's Association International Conference Satellite Symposium..
18:1957-1968.
2022
-
Characterization of gene expression patterns in mild cognitive impairment using a transcriptomics approach and neuroimaging endophenotypes..
18:2493-2508.
2022
-
Deep residual inception encoder-decoder network for amyloid PET harmonization..
18:2448-2457.
2022
-
Neuropathological lesions and their contribution to dementia and cognitive impairment in a heterogeneous clinical population..
18:2403-2412.
2022
-
Protein phosphatase 2A and complement component 4 are linked to the protective effect of APOE ɛ2 for Alzheimer's disease..
18:2042-2054.
2022
-
Mild behavioral impairment is associated with progression to Alzheimer's disease: A clinicopathological study..
18:2199-2208.
2022
-
Replication study of AD-associated rare variants..
18:858-862.
2022
-
Sex differences in cognitive resilience in preclinical autosomal-dominant Alzheimer's disease carriers and non-carriers: Baseline findings from the API ADAD Colombia Trial..
18:2272-2282.
2022
-
Traumatic brain injury and dementia risk in male veteran older twins-Controlling for genetic and early life non-genetic factors..
18:2234-2242.
2022
-
Primary prevention recommendations to reduce the risk of cognitive decline..
18:1569-1579.
2022
-
Late-life physical activity relates to brain tissue synaptic integrity markers in older adults..
18:2023-2035.
2022
-
Lean mass, grip strength, and hospital-associated disability among older adults in Health ABC..
18:1898-1906.
2022
-
Dysphagia Evaluation in a Multidisciplinary VA Cognitive Care Clinic..
-.
2022
-
Screening for Memory Concerns at the Well-Woman Visit..
-.
2022
-
The Care Ecosystem: The Effectiveness and Implementation of Telephone-Based Collaborative Dementia Care..
-.
2022
-
The small HDL particle hypothesis of Alzheimer's disease..
19:391-404.
2022
-
Whole genome sequencing-based copy number variations reveal novel pathways and targets in Alzheimer's disease..
18:1846-1867.
2021
-
Black and White individuals differ in dementia prevalence, risk factors, and symptomatic presentation..
18:1461-1471.
2021
-
Different rates of cognitive decline in autosomal dominant and late-onset Alzheimer disease..
18:1754-1764.
2021
-
Assessing cognition in the era of COVID19: Do we need methods to assess cognitive function virtually?.
17 Suppl 8:-.
2021
-
Type and frequency of social contacts associated with low mood before and during the COVID-19 pandemic in older adults: I-CONECT project..
17 Suppl 11:-.
2021
-
ARMADA: Assessing reliable measurement in Alzheimer's disease and cognitive aging project methods..
18:1449-1460.
2021
-
Plasma amyloid beta, neurofilament light chain, and total tau in the Systolic Blood Pressure Intervention Trial (SPRINT)..
18:1472-1483.
2021
-
Assessing bidirectional associations between cognitive impairment and late age-related macular degeneration in the Age-Related Eye Disease Study 2..
18:1296-1305.
2021
-
The costs of developing treatments for Alzheimer's disease: A retrospective exploration..
18:469-477.
2021
-
Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease..
18:824-857.
2021
-
Relationships among tau burden, atrophy, age, and naming in the aphasic variant of Alzheimer's disease..
17:1788-1797.
2021
-
Decoding perineuronal net glycan sulfation patterns in the Alzheimer's disease brain..
18:942-954.
2021
-
Epigenomic features related to microglia are associated with attenuated effect of APOE ε4 on Alzheimer's disease risk in humans..
18:688-699.
2021
-
Why the cognitive "fountain of youth" may be upstream: Pathways to dementia risk and resilience through social connectedness..
18:934-941.
2021
-
Aducanumab: Appropriate use recommendations..
18:531-533.
2021
-
Characterizing plasma NfL in a community-dwelling multi-ethnic cohort: Results from the HABLE study..
18:240-250.
2021
-
Insomnia symptom severity and cognitive performance: Moderating role of APOE genotype..
18:408-421.
2021
-
Plasma IL-12/IFN-γ axis predicts cognitive trajectories in cognitively unimpaired older adults..
18:645-653.
2021
-
A blood screening tool for detecting mild cognitive impairment and Alzheimer's disease among community-dwelling Mexican Americans and non-Hispanic Whites: A method for increasing representation of diverse populations in clinical research..
18:77-87.
2021
-
Subjective cognitive decline and objective cognition among diverse U.S. Hispanics/Latinos: Results from the Study of Latinos-Investigation of Neurocognitive Aging (SOL-INCA)..
18:43-52.
2021
-
State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease..
18:159-177.
2021
-
Suicide risk in first year after dementia diagnosis in older adults..
18:262-271.
2021
-
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS): Framework and methodology..
17:2043-2055.
2021
-
Network dysfunction in cognitively normal APOE ε4 carriers is related to subclinical tau..
18:116-126.
2021
-
Validation and demonstration of a new comprehensive model of Alzheimer's disease progression..
17:1698-1708.
2021
-
Body mass index in early adulthood and dementia in late life: Findings from a pooled cohort..
17:1798-1807.
2021
-
Diagnostic criteria for apathy in neurocognitive disorders..
17:1892-1904.
2021
-
Reduced synchrony in alpha oscillations during life predicts post mortem neurofibrillary tangle density in early-onset and atypical Alzheimer's disease..
17:2009-2019.
2021
-
Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel..
17:1528-1553.
2021
-
Functional decline in the aphasic variant of Alzheimer's disease..
17:1641-1648.
2021
-
Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research..
17:1554-1574.
2021
-
Deepen into sleep and wake patterns across Alzheimer's disease phenotypes..
17:1403-1406.
2021
-
Extrapyramidal signs and Alzheimer's disease prognosis in a multiethnic, community-based sample of demented elders..
17:1465-1473.
2021
-
Cognitive measures lacking in EHR prior to dementia or Alzheimer's disease diagnosis..
17:1231-1243.
2021
-
Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve..
17:1329-1341.
2021
-
Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study..
17:1353-1364.
2021
-
Associations between plasma neurofilament light, in vivo brain pathology, and cognition in non-demented individuals with autosomal-dominant Alzheimer's disease..
17:813-821.
2021
-
Brain structures and networks responsible for stimulation-induced memory flashbacks during forniceal deep brain stimulation for Alzheimer's disease..
17:777-787.
2021
-
Integrative functional genomic analysis of intron retention in human and mouse brain with Alzheimer's disease..
17:984-1004.
2021
-
Modeling autosomal dominant Alzheimer's disease with machine learning..
17:1005-1016.
2021
-
Traumatic brain injury alters neuropsychiatric symptomatology in all-cause dementia..
17:686-691.
2021
-
Alzheimer's disease biomarkers in Black and non-Hispanic White cohorts: A contextualized review of the evidence..
18:1545-1564.
2021
-
EPIGENOMIC FEATURES RELATED TO MICROGLIA ARE ASSOCIATED WITH ATTENUATED EFFECT OF APOE ε4 ON ALZHEIMER'S DISEASE RISK IN HUMANS..
16.
2020
-
Utility of MRI in the identification of hippocampal sclerosis of aging..
17:847-855.
2020
-
Vascular health across young adulthood and midlife cerebral autoregulation, gait, and cognition..
17:745-754.
2020
-
Gene- and age-informed screening for preclinical Alzheimer's disease trials..
17:457-465.
2020
-
Development and validation of the Uniform Data Set (v3.0) executive function composite score (UDS3-EF)..
17:574-583.
2020
-
Item response theory analysis of the Clinical Dementia Rating..
17:534-542.
2020
-
Toward a theory-based specification of non-pharmacological treatments in aging and dementia: Focused reviews and methodological recommendations..
17:255-270.
2020
-
Open Peer Commentary to "Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019"..
17:702-703.
2020
-
Mitophagy alterations in Alzheimer's disease are associated with granulovacuolar degeneration and early tau pathology..
17:417-30.
2020
-
Vascular contributions to cognitive impairment and dementia (VCID): A report from the 2018 National Heart, Lung, and Blood Institute and National Institute of Neurological Disorders and Stroke Workshop..
16:1714-1733.
2020
-
The Brain Chart of Aging: Machine-learning analytics reveals links between brain aging, white matter disease, amyloid burden, and cognition in the iSTAGING consortium of 10,216 harmonized MR scans..
17:89-102.
2020
-
Education differentially contributes to cognitive reserve across racial/ethnic groups..
17:70-80.
2020
-
Tau and apolipoprotein E modulate cerebrovascular tight junction integrity independent of cerebral amyloid angiopathy in Alzheimer's disease..
16:1372-1383.
2020
-
Perspective on the "African American participation in Alzheimer disease research: Effective strategies" workshop, 2018..
16:1734-1744.
2020
-
Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer's disease, and the role APOE carrier status..
16:1663-1673.
2020
-
Genome-wide transcriptome analysis identifies novel dysregulated genes implicated in Alzheimer's pathology..
16:1213-1223.
2020
-
Incident dementia and faster rates of cognitive decline are associated with worse multisensory function summary scores..
16:1384-1392.
2020
-
Difficulty and help with activities of daily living among older adults living alone with cognitive impairment..
16:1125-1133.
2020
-
Genome-wide association study of rate of cognitive decline in Alzheimer's disease patients identifies novel genes and pathways..
16:1134-1145.
2020
-
Cognitive tests aid in clinical differentiation of Alzheimer's disease versus Alzheimer's disease with Lewy body disease: Evidence from a pathological study..
16:1173-1181.
2020
-
MAPT haplotype-stratified GWAS reveals differential association for AD risk variants..
16:983-1002.
2020
-
Measurement and characterization of distinctive clinical phenotypes using the Frontotemporal Lobar Degeneration Module (FTLD-MOD)..
16:918-925.
2020
-
Cerebrospinal fluid biomarkers of neurodegeneration, synaptic dysfunction, and axonal injury relate to atrophy in structural brain regions specific to Alzheimer's disease..
16:883-895.
2020
-
Association of traumatic brain injury with dementia and memory decline in older adults in the United States..
16:853-861.
2020
-
A novel sensitive assay for detection of a biomarker of pericyte injury in cerebrospinal fluid..
16:821-830.
2020
-
A roadmap to advance delirium research: Recommendations from the NIDUS Scientific Think Tank..
16:726-733.
2020
-
Neurovascular and immune mechanisms that regulate postoperative delirium superimposed on dementia..
16:734-749.
2020
-
International drive to illuminate delirium: A developing public health blueprint for action..
16:711-725.
2020
-
Shared neural substrates of cognitive function and postural control in older adults..
16:621-629.
2020
-
Complex interactions underlie racial disparity in the risk of developing Alzheimer's disease dementia..
16:589-597.
2020
-
Impact of deprescribing AChEIs on aggressive behaviors and antipsychotic prescribing..
16:630-640.
2020
-
Risk factors for earlier dementia onset in autopsy-confirmed Alzheimer's disease, mixed Alzheimer's with Lewy bodies, and pure Lewy body disease..
16:524-530.
2020
-
Spatial navigation ability predicts progression of dementia symptomatology..
16:491-500.
2020
-
Brain imaging measurements of fibrillar amyloid-β burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE ε4 allele..
16:598-609.
2020
-
Plasma biomarkers of astrocytic and neuronal dysfunction in early- and late-onset Alzheimer's disease..
16:681-695.
2020
-
Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration..
16:49-59.
2020
-
Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration..
16:37-48.
2020
-
Use of the CDR® plus NACC FTLD in mild FTLD: Data from the ARTFL/LEFFTDS consortium..
16:79-90.
2020
-
Whitepaper: Defining and investigating cognitive reserve, brain reserve, and brain maintenance..
16:1305-1311.
2020
-
Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD..
16:552-560.
2020
-
Intact global cognitive and olfactory ability predicts lack of transition to dementia..
16:326-334.
2020
-
Active lifestyles moderate clinical outcomes in autosomal dominant frontotemporal degeneration..
16:91-105.
2020
-
Apolipoprotein E genotype and the association between C-reactive protein and postoperative delirium: Importance of gene-protein interactions..
16:572-580.
2020
-
Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint..
16:11-21.
2020
-
Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN)..
16:219-228.
2020
-
Concordance of Lumipulse cerebrospinal fluid t-tau/Aβ42 ratio with amyloid PET status..
16:144-152.
2020
-
Health-care use and cost for multimorbid persons with dementia in the National Health and Aging Trends Study..
16:1224-1233.
2020
-
A research framework for cognitive aging and Alzheimer's disease among diverse US Latinos: Design and implementation of the Hispanic Community Health Study/Study of Latinos-Investigation of Neurocognitive Aging (SOL-INCA)..
15:1624-1632.
2019
-
Prevalence and correlates of mild cognitive impairment among diverse Hispanics/Latinos: Study of Latinos-Investigation of Neurocognitive Aging results..
15:1507-1515.
2019
-
Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial..
15:1427-1436.
2019
-
Objective napping, cognitive decline, and risk of cognitive impairment in older men..
15:1039-1047.
2019
-
Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease..
15:655-665.
2019
-
Ethnoracial differences in Alzheimer's disease from the FLorida Autopsied Multi-Ethnic (FLAME) cohort..
15:635-643.
2019
-
Clinical and cortical decline in the aphasic variant of Alzheimer's disease..
15:543-552.
2019
-
Genetic screen in a large series of patients with primary progressive aphasia..
15:553-560.
2019
-
Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease..
15:487-496.
2018
-
Military-related risk factors for dementia..
14:1651-1662.
2018
-
Hypertension and obesity moderate the relationship between β-amyloid and cognitive decline in midlife..
15:418-428.
2018
-
Community perceptions related to brain donation: Evidence for intervention..
15:267-272.
2018
-
Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease..
14:1427-1437.
2018
-
Progress and future challenges in aging and diversity research in the United States..
15:995-1003.
2018
-
Reduce the burden of dementia now..
14:845-847.
2018
-
Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts..
14:1193-1203.
2018
-
PET staging of amyloidosis using striatum..
14:1281-1292.
2018
-
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease..
14:535-562.
2018
-
Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease..
14:869-879.
2018
-
Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging..
14:1460-1469.
2018
-
Driving cessation over a 24-year period: Dementia severity and cerebrospinal fluid biomarkers..
14:610-616.
2018
-
Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study..
14:280-292.
2017
-
Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms..
14:205-214.
2017
-
Innovation in care for individuals with cognitive impairment: Can reimbursement policy spread best practices?.
13:1168-1173.
2017
-
Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial magnetic resonance imaging study..
14:43-53.
2017
-
Post-traumatic stress disorder and risk of dementia among members of a health care delivery system..
14:28-34.
2017
-
Objective features of subjective cognitive decline in a United States national database..
13:1337-1344.
2017
-
Family history and TOMM40 '523 interactive associations with memory in middle-aged and Alzheimer's disease cohorts..
13:1217-1225.
2017
-
Tau and amyloid β proteins distinctively associate to functional network changes in the aging brain..
13:1261-1269.
2017
-
Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β..
13:1004-1012.
2017
-
Cerebrospinal fluid markers detect Alzheimer's disease in nonamnestic dementia..
13:598-601.
2017
-
Transethnic genome-wide scan identifies novel Alzheimer's disease loci..
13:727-738.
2017
-
Executive function, episodic memory, and Medicare expenditures..
13:792-800.
2017
-
Clinical outcomes in older surgical patients with mild cognitive impairment..
14:590-600.
2017
-
The Vascular Impairment of Cognition Classification Consensus Study..
13:624-633.
2016
-
A candidate regulatory variant at the TREM gene cluster associates with decreased Alzheimer's disease risk and increased TREML1 and TREM2 brain gene expression..
13:663-673.
2016
-
Implementation of subjective cognitive decline criteria in research studies..
13:296-311.
2016
-
Sex biology contributions to vulnerability to Alzheimer's disease: A think tank convened by the Women's Alzheimer's Research Initiative..
12:1186-1196.
2016
-
Decreased hippocampal metabolism in high-amyloid mild cognitive impairment..
12:1288-1296.
2016
-
Apathy associated with neurocognitive disorders: Recent progress and future directions..
13:84-100.
2016
-
MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies..
12:1297-1304.
2016
-
The Predictors study: Development and baseline characteristics of the Predictors 3 cohort..
13:20-27.
2016
-
Tau: From research to clinical development..
12:1033-1039.
2016
-
Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trials..
12:631-2.
2016
-
Challenges, solutions, and recommendations for Alzheimer's disease combination therapy..
12:623-30.
2016
-
Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit..
12:614-22.
2016
-
Report on milestones for care and support under the U.S. National Plan to Address Alzheimer's Disease..
12:334-69.
2016
-
Beta-amyloid and cognitive decline in late middle age: Findings from the Wisconsin Registry for Alzheimer's Prevention study..
12:805-14.
2016
-
Endogenous sex hormones and cognitive function in older women..
12:758-65.
2016
-
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria..
12:292-323.
2016
-
The short-term and long-term relationship between delirium and cognitive trajectory in older surgical patients..
12:766-75.
2016
-
Surgery is associated with ventricular enlargement as well as cognitive and functional decline..
12:590-7.
2015
-
Influence of amyloid and APOE on cognitive performance in a late middle-aged cohort..
12:281-91.
2015
-
Guidelines for reporting methodological challenges and evaluating potential bias in dementia research..
11:1098-109.
2015
-
Massachusetts Alzheimer's Disease Research Center: progress and challenges..
11:1241-5.
2015
-
Imaging-based enrichment criteria using deep learning algorithms for efficient clinical trials in mild cognitive impairment..
11:1489-1499.
2015
-
Genetically predicted body mass index and Alzheimer's disease-related phenotypes in three large samples: Mendelian randomization analyses..
11:1439-1451.
2015
-
Manual segmentation qualification platform for the EADC-ADNI harmonized protocol for hippocampal segmentation project..
11:161-74.
2015
-
Relationship between hippocampal atrophy and neuropathology markers: a 7T MRI validation study of the EADC-ADNI Harmonized Hippocampal Segmentation Protocol..
11:139-50.
2015
-
Statins and brain integrity in older adults: secondary analysis of the Health ABC study..
11:1202-11.
2015
-
APOE ε4 and risk for Alzheimer's disease: do regionally distributed white matter hyperintensities play a role?.
10:619-29.
2014
-
2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease..
10:S430-52.
2014
-
The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: evidence of validity..
11:111-25.
2014
-
Subjective cognitive concerns, episodic memory, and the APOE ε4 allele..
10:752-759.e1.
2014
-
Harmonized benchmark labels of the hippocampus on magnetic resonance: the EADC-ADNI project..
11:151-60.e5.
2014
-
Delphi definition of the EADC-ADNI Harmonized Protocol for hippocampal segmentation on magnetic resonance..
11:126-38.
2014
-
Survival and early recourse to care for dementia: A population based study..
11:385-93.
2014
-
At the interface of sensory and motor dysfunctions and Alzheimer's disease..
11:70-98.
2014
-
Biomarker progressions explain higher variability in stage-specific cognitive decline than baseline values in Alzheimer disease..
10:690-703.
2014
-
Association of fish oil supplement use with preservation of brain volume and cognitive function..
11:226-35.
2014
-
Depression and dementias among military veterans..
10:S166-73.
2014
-
Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative..
10:S226-35.
2014
-
Lifestyle and health-related risk factors and risk of cognitive aging among older veterans..
10:S111-21.
2014
-
Prisoner of war status, posttraumatic stress disorder, and dementia in older veterans..
10:S236-41.
2014
-
Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors..
11:415-24.
2014
-
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease..
10:844-52.
2014
-
Social cognition in Alzheimer's disease: a separate construct contributing to dependence..
10:818-26.
2014
-
Health-care use and cost in dementia caregivers: Longitudinal results from the Predictors Caregiver Study..
11:444-54.
2014
-
Public beliefs and knowledge about risk and protective factors for Alzheimer's disease..
10:S381-9.
2014
-
Microdosing of scopolamine as a "cognitive stress test": rationale and test of a very low dose in an at-risk cohort of older adults..
10:262-7.
2014
-
A point-based tool to predict conversion from mild cognitive impairment to probable Alzheimer's disease..
10:646-55.
2014
-
Development and validation of a brief dementia screening indicator for primary care..
10:656-665.e1.
2014
-
Aging children of long-lived parents experience slower cognitive decline..
10:S315-22.
2013
-
Plasma nutrient status of patients with Alzheimer's disease: Systematic review and meta-analysis..
10:485-502.
2013
-
The source of cognitive complaints predicts diagnostic conversion differentially among nondemented older adults..
10:319-27.
2013
-
Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future..
9:602-8.
2013
-
Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease..
9:123-131.e1.
2013
-
Establishing the psychometric underpinning of cognition measures for clinical trials of Alzheimer's disease and its precursors: a new approach..
9:S56-60.
2013
-
Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging..
9:S72-83.
2013
-
New ELISAs with high specificity for soluble oligomers of amyloid β-protein detect natural Aβ oligomers in human brain but not CSF..
9:99-112.
2013
-
Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer's disease..
9:733-40.
2013
-
Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association..
9:e-1-16.
2013
-
CSF biomarker variability in the Alzheimer's Association quality control program..
9:251-61.
2013
-
Putting the Alzheimer's cognitive test to the test I: traditional psychometric methods..
9:S4-9.
2012
-
Putting the Alzheimer's cognitive test to the test II: Rasch Measurement Theory..
9:S10-20.
2012
-
Long-term anticholinergic use and the aging brain..
9:377-85.
2012
-
Dementia and out-of-pocket spending on health care services..
9:19-29.
2012
-
Advancing Alzheimer's disease diagnosis, treatment, and care: recommendations from the Ware Invitational Summit..
8:445-52.
2012
-
Metabolic syndrome and localization of white matter hyperintensities in the elderly population..
8:S88-95.e1.
2012
-
The epidemiology of Alzheimer's disease: laying the foundation for drug design, conduct, and analysis of clinical trials..
8:237-42.
2012
-
Citalopram for agitation in Alzheimer's disease: design and methods..
8:121-30.
2012
-
Functional deficits among patients with mild cognitive impairment..
7:611-4.
2011
-
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup..
7:367-85.
2011
-
Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease..
7:474-485.e4.
2011
-
Assessment of cognition in early dementia..
7:e60-e76.
2011
-
Executive function and instrumental activities of daily living in mild cognitive impairment and Alzheimer's disease..
7:300-8.
2011
-
Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease..
7:257-62.
2011
-
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease..
7:280-92.
2011
-
Developing a global strategy to prevent Alzheimer's disease: Leon Thal Symposium 2010..
7:127-32.
2011
-
National estimates of the prevalence of Alzheimer's disease in the United States..
7:61-73.
2011
-
Operationalizing diagnostic criteria for Alzheimer's disease and other age-related cognitive impairment-Part 2..
7:35-52.
2011
-
Reducing case ascertainment costs in U.S. population studies of Alzheimer's disease, dementia, and cognitive impairment-Part 1..
7:94-109.
2011
-
Sources of variability in estimates of the prevalence of Alzheimer's disease in the United States..
7:74-9.
2011
-
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers..
7:386-395.e6.
2011
-
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease..
7:270-9.
2011
-
Trends in the incidence and prevalence of Alzheimer's disease, dementia, and cognitive impairment in the United States..
7:80-93.
2011
-
Dependence as a unifying construct in defining Alzheimer's disease severity..
6:482-93.
2010
-
Commentary on "Developing a national strategy to prevent dementia: Leon Thal Symposium 2009." Dementia risk indices: A framework for identifying individuals with a high dementia risk..
6:138-41.
2010
-
Cognitive performance and informant reports in the diagnosis of cognitive impairment and dementia in African Americans and whites..
5:445-53.
2009
-
"Below average" self-assessed school performance and Alzheimer's disease in the Aging, Demographics, and Memory Study..
5:380-7.
2009
-
Scales as outcome measures for Alzheimer's disease..
5:324-39.
2009
-
Telephone interview for cognitive status: Creating a crosswalk with the Mini-Mental State Examination..
5:492-7.
2009
-
Revision of the apolipoprotein E compensatory mechanism recruitment hypothesis..
4:251-4.
2008
-
Comparison of costs of care between patients with Alzheimer's disease and dementia with Lewy bodies..
4:280-4.
2008
-
Trends in the prevalence and mortality of cognitive impairment in the United States: is there evidence of a compression of cognitive morbidity?.
4:134-44.
2008
-
Role of biomarkers in studies of presymptomatic Alzheimer's disease..
1:145-51.
2005
Identity
International Standard Serial Number (ISSN)